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The “common variant—common disease” hypothesis was proposed to explain diseases
with strong inheritance. This model suggests that a genetic disease is the result
of the combination of several common genetic variants. Common genetic variants
are described as a 5% frequency differential between diseased vs. matched control
populations. This theory was recently supported by an epidemiology paper stating
that about 50% of genetic risk for autism resides in common variants. However, rare
variants, rather than common variants, have been found in numerous genome wide
genetic studies and many have concluded that the “common variant—common disease”
hypothesis is incorrect. One interpretation is that rare variants are major contributors to
genetic diseases and autism involves the interaction of many rare variants, especially
in the brain. It is obvious there is much yet to be learned about autism genetics.
Evidence has been mounting over the years indicating immune involvement in autism,
particularly the HLA genes on chromosome 6 and KIR genes on chromosome 19.
These two large multigene complexes have important immune functions and have
been shown to interact to eliminate unwanted virally infected and malignant cells. HLA
proteins have important functions in antigen presentation in adaptive immunity and
specific epitopes on HLA class I proteins act as cognate ligands for KIR receptors in
innate immunity. Data suggests that HLA alleles and KIR activating genes/haplotypes
are common variants in different autism populations. For example, class I allele (HLA-A2
and HLA-G 14 bp-indel) frequencies are significantly increased by more than 5% over
control populations (Table 2). The HLA-DR4 Class II and shared epitope frequencies are
significantly above the control populations (Table 2). Three activating KIR genes: 3DS1,
2DS1, and 2DS2 have increased frequencies of 15, 22, and 14% in autism populations,
respectively. There is a 6% increase in total activating KIR genes in autism over control
subjects. And, more importantly there is a 12% increase in activating KIR genes and their
cognate HLA alleles over control populations (Torres et al., 2012a). These data suggest
the interaction of HLA ligand/KIR receptor pairs encoded on two different chromosomes
is more significant as a ligand/receptor complex than separately in autism.
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INTRODUCTION
Understanding genetic contribution in autism spectrum disorder
(ASD) is a major challenge due to genetic complexities of a
multifaceted disease. ASD is a puzzling neurodevelopmental
condition characterized behaviorally by deficits in social-
communication and the presences of restrictive stereotyped
behaviors with involvement of genetic, environmental, and
neurological components. Although, multiple etiologies are
purported to exist, several studies have noted a strong familial
clustering suggesting that heredity is of major importance
(Bolton et al., 1994; Bailey et al., 1995; Constantino et al., 2013).
The study of human genetics has advanced rapidly over
the last 30 years and researchers have adopted new and better
methods in an attempt to unravel the extraordinary genomic
complexity of autism. An early attempt to find DNA regions
that associate with ASD involved the examination of several
hundred microsatellites (also known as short tandem repeats)
across the genome (Lamb et al., 2000). It became apparent early
on that this was not answering questions about autism genetics
and this approach was largely abandoned. A significant flaw
in these early studies involved the use of siblings as control
populations (Philippe et al., 1999). It is now thought that siblings
of subjects with autism are unsuitable controls as they have
many of the same risk polymorphisms as their autistic siblings.
The next attempt involved the studies of purported autism
candidate genes. This research typically involved the examination
of single nucleotide polymorphisms (SNPs) between subjects
and controls in a candidate gene thought to be involved in
the etiology of autism. Although a few candidate genes were
identified with apparent association to autism, overall the studies
hypothesizing the involvement of purported candidate genes
were often contradictory and proved to be unreliable (State,
2010).
Genome wide association studies (GWAS) that examine over
half a million SNPs have been a little more successful in
identifying rare genetic variants (rare variants) in a small number
of ASD cases; however, common genetic variants (common
variants) have not clearly been identified in GWAS studies
(Goldstein, 2009; Manolio et al., 2009; Tao et al., 2016). One
interpretation is that rare variants are major contributors to
genetic diseases (McClellan and King, 2010) and that ASD
involves the interaction of many rare variants, especially in
the brain (Irimia et al., 2014; Krystal and State, 2014). The
newest research tool involves whole genome sequencing (WGS)
to determine the DNA sequence of an individual’s entire
genome. On the surface this sounds all encompassing; however,
weaknesses of this approach besides cost include distorted
amplification of certain DNA targets and the difficulty in aligning
SNPs to the proper chromosome (Laver et al., 2016).
Several studies have noted a strong familial clustering
suggesting that heredity of risk-associated genes is about 50–
60% and that about 50% of this risk resides in common variants
(Gaugler et al., 2014). The “common variant-common disease”
hypothesis was proposed nearly a 100 years ago to explain
common diseases with a strong genetic association (Fisher, 1918).
This model suggests that each common risk variant (greater or
less than 5% of the control population) confers a small degree of
risk and that a genetic disease is the result of the combination
of several common variants. Common variants (low penetrance)
are genetically old and found in multiple populations, whereas
rare variants (high penetrance) are new and found in specific
populations (Schork et al., 2009). The examination of whole-
genome sequence data of autism quartet families (two autism
affected siblings and parents) suggested that the majority (69%)
of autism affected siblings carried different rare variantmutations
(Yuen et al., 2015), supporting the idea that these rare variants
are not established in the studied population. Over the years,
much attention has been given to discovering the genetic
underpinnings of ASD; however, immune abnormalities have
consistently been found in this disorder, and recently the number
and impact of immune studies has reached a crescendo, including
in the area of immunogenetics (Westover et al., 2011; Sweeten
and McDougle, 2016; Young et al., 2016).
BASIC IMMUNE SYSTEM
Immunology is the study of a system of molecules, tissue and
cells that recognize and attack foreign invaders and abnormal
cells that endanger the individual. The entire set of immune
genes that contribute to immune function is now referred to as
the “Immunome” consisting of about 900 genes across various
chromosomes that encode a variety of different proteins to
accomplish immune surveillance (Ortutay and Vihinen, 2009).
A major component of the immune system involves genes in
the major histocompatibility complex (MHC) on chromosome
6 in humans. The MHC encodes human leukocyte antigen
(HLA) proteins and the terms HLA and MHC are often
used interchangeably. The human immune system has two
main components, the innate immune system and the adaptive
immune system. Both systems have humoral and cellular
components (Figure 1), but innate immunity is generally
considered to be non-specific whereas humoral immunity
provides a specific response to pathogens and foreign antigens.
Innate immunity is germ-line encoded, does not adapt after
exposure to antigens, and is constitutively expressed leading to
an immediate and rapid response to antigens. This is the first line
of defense against pathogens, utilizing complement activation
and other mechanisms to destroymost microorganisms, typically
within hours of exposure.
The classical class I HLA proteins, expressed on essentially all
nucleated cells of the body, serve as transducers by presenting
antigens to T-cell and B-cell receptors, thereby activating the
adaptive immune system for cellular cytotoxicity and antibody
production, respectively. The adaptive HLA class II genes
produce proteins expressed by specialized immune cells to
present antigens to T-cells. HLA-class II genes can recombine by
somatic mutation allowing for broad antigen adaptation. HLA-
class I and II alleles are some of the most genetically variable
coding loci in mammals.
INNATE IMMUNITY COMPONENTS
The innate system has soluble complement proteins that
help or “complement” the clearance of pathogens in various
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FIGURE 1 | The two branches of the immune system: Boxes display humoral and cellular components in innate and adaptive immunity.
ways, including acting as an opsonin and by forming a
membrane attack complex to kill cells. The complement system
contains over 25 proteins and protein fragments that are
mainly synthesized in the liver, but also exist in the brain.
The innate cellular components include a variety of cell
surface and cytoplasmic pattern recognition receptors (PRR)
expressed by granulocytes, macrophages, and dendritic cells
which bind to pathogen-associated molecular patterns (PAMPs)
associated with components of microorganisms. An innate
cellular system important in removing aberrant cells (virally
infected and transformed) involves the interaction of HLA
cognate receptors with killer-cell immunoglobulin-like receptors
(KIRs) on NK-cells.
ADAPTIVE IMMUNITY COMPONENTS
HLA proteins are important in presenting antigen to CD4+
(helper T-cells) and CD8+ (cytotoxic T-cells) and the
extraordinary diversity in HLA alleles allows for exquisitely
sensitive antigen recognition. Adaptive immune responses are
slower than those elicited by the innate immune system; however,
long term immunological memory is invoked. Memory involves
the recognition of antigens from invading organism for extended
periods of time, often decades. This is accomplished by the
creation of tailor-made memory cells. Antibodies are the main
soluble component of the adaptive system; however, cytokines
are also important. Memory cells will continue to survive in
the body for decades then re-exposure to the antigen activate
them to produce the respective antibodies in unlimited numbers.
This production of numerous antibodies is accomplished by
gene recombination in B-cells followed by a complicated cellular
selection process which results in antibodies that are very
specific to the foreign antigens. The adaptive immune system
is comprised of the cellular components T and B-cells. T-cells
have cell-surface receptors that recognize peptides bound to
HLA class I and class II proteins, a critical step in cell-mediated
immunity.
The cellular components of the adaptive immune system
involve T and B-cells. T-cells are important in cell-mediated
immunity and are distinguished by the T-cell receptors which
recognize short peptides bound to HLA class I and class II
proteins. Several subsets of T-cells with distinct functions exist.
For example, cytotoxic T-cells seek and destroy virally infected
cells and tumor cells while helper T-cells activate macrophages
and assist B-cells to mature into antibody producing plasma cells
and memory B-cells.
IMMUNITY AND AUTISM
One of the earliest immune associations observed in ASD was
by Stubbs et al. (1985) when they noted that pairs of ASD
affected children share HLA haplotypes more often than non-
affected pairs. The HLA complex is of major interest in medical
research as genes/proteins in this region are involved in many
immune processes such as organ transplantation, autoimmunity,
resistance to specific pathogens, inflammation, ligands for
immune cell receptors, and the complement cascade. There is
now considerable evidence from association and linkage studies
that suggests the involvement of HLA alleles/genes/haplotypes in
the etiology of ASD (Torres et al., 2006, 2012a).
HLA GENE COMPLEX
The HLA complex is fascinating as there are about 200 genes
that encode proteins with various functions including ligands,
receptors, cytokines, signaling factors, heat shock proteins,
transcription regulators, and most importantly the recognition
of self from non-self. The HLA gene map in Figure 2 (Shiina
et al., 2009) illustrates this complexity. The entire 200 HLA gene
region is inherited as a single 4.5 million base pair extended
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FIGURE 2 | Gene map of the human leukocyte antigen (HLA) region. The major histocompatibility complex (MHC) gene map corresponds to the genomic
coordinates of 29,677,984 (GABBR1) to 33,485,635 (KIFC1) in the human genome build 36.3 of the National Center for Biotechnology Information (NCBI) map viewer.
The regions separated by arrows show the HLA subregions such as extended class I, classical class I, class III, classical class II, and extended class II regions from
telomere (left and top side) to centromere (right and bottom side). White, gray, striped and black boxes show expressed genes, gene candidates, non-coding genes
and pseudogenes, respectively. The location of the alpha, beta, and kappa blocks containing the cluster of duplicated HLA class I genes in the class I region are
indicated. Reprinted with permission from Shiina et al. (2009).
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haplotype of which there are thousands; most very rare. A
genetic haplotype is a contiguous combination of DNA sequences
inherited on a single chromosome: eight of the more common
extended haplotypes with strong disease associations have been
entirely DNA sequenced (Horton et al., 2008). Various extended
haplotypes containing millions of base pairs can have identical
smaller haplotypes within their borders meaning that they must
be carefully examined. Haplotype structure can be important
in the understanding of allele-specific events such as protein
structure, methylation, outcomes in transplantation, and disease
prediction (McQueen et al., 2007). The HLA gene map does not
fully illustrate the complexity of the class I and class II regions
that have thousands of alleles important in determining self from
non-self.
HLA CLASS I ASD ASSOCIATIONS
There are numerous ASD associations with alleles/genes in the
HLA region. For example, three different research groups have
demonstrated a significant association between ASD and the
HLA-A2 (A2) allele (Ferrante et al., 2003; Torres et al., 2006; Al-
Hakbany et al., 2014). Gourraud et al. (2014) noted that there are
over 100,000 SNPs in the 4.5 million base pairs of HLA (1 out
of every 45 bases) and concluded that whole genome screening
methods like GWAS are not suited for interrogating HLA
polymorphisms. They referred to this extreme HLA diversity as
a “genome within a genome.” Table 1 illustrates the complexity
of SNPs in a small region of the HLA-A-locus. Site specific
primers (SSP) PCR assays clearly and inexpensively identify these
complex HLA polymorphisms (Bunce and Passey, 2013). Other
HLA class I and II loci have similar SNP complexity as do
KIR genes, but none of these sets of polymorphisms are readily
detected by GWAS techniques.
It has recently been reported in the Thai population that
certain HLA-B alleles (B13:02, B35:02, B44:03, and B56:01) are
significantly associated with ASD while two others (B18:02 and
B46:12) are associated in a protective manner (Puangpetch et al.,
2015). This is not surprising as certain HLA extended haplotypes
which have about 200 genes including specific HLA-A, B, and C
alleles have very strong associations with ASD. For example, in
the Caucasian population HLA-B44 and B15 alleles as part of
extended haplotypes 44.1 and 62.1, respectively, are associated
with ASD (Torres et al., 2012a).
HLA-G non-classical I molecules are expressed during
pregnancy on trophoblast cells that interact with leukocyte-
associated immunoglobulin-like receptor (LAIR) and KIR
(2DL4) molecules expressed by maternal NK-cells at the uterine
fetal/maternal interface to suppress normal immune responses
(Tilburgs et al., 2015). A 14 bp deletion in the HLA-G 3′-UTR
is associated with higher levels of HLA-G expression whereas a
14 bp insertion associates with reduced HLA-G levels. Guerini
et al. (2015) have shown that ASD subjects have an increase in
the 14 bp insertion and lower levels of soluble HLA-G protein.
This suggests that ASD subjects and their mothers have less
HLA-G-mediated immune tolerance during pregnancy. Human
non-classical HLA I molecules could be important in brain
development as it has recently been shown that non-classical
MHC class I molecules are expressed in the olfactory bulb,
hippocampus, cerebellum, and nerve nuclei in the developing
embryonic mouse brain (Liu et al., 2015).
A main function of HLA class I molecules is to present
antigens to CD8+ T-cells, thus starting the complex immune
process that creates cytotoxic T-cells to attack specific targets.
Any gene in an extended haplotype may be the candidate ASD
gene and other HLA alleles may be passengers, however, the
identification of foreign peptides that bind to A2 could suggest
microorganisms that may be involved in the etiology of ASD.
Our data suggests that the HLA class I proteins cognate ligands
for KIR are important in autism and that other NK-cell killing
receptors could also be important (Figure 4). This interaction
does not involve peptide binding as KIR receptors recognize
specific amino acid sequences of certain HLA cognate protein
ligands (Parham and Moffett, 2013). HLA class I A, B, C alleles
all behave as antigen presenting ligands for self and nonself-
peptides; however, only certain HLA-A, B, C alleles are ligands
for KIR cell surface proteins. Although the HLA cognate ligand
site slightly overlaps the peptide binding site, it has a separate
function (Figure 3). Specific HLA ligands that bind to KIR
activating receptors have been shown to be increased in ASD
(Torres et al., 2012b, 2016; Guerini et al., 2014). It should be
mentioned that the HLA-A2 does not behave as a KIR ligand.
It was only a few years ago that the brain was considered
immune privileged, being protected from immune fluctuations
by the blood brain barrier. Today there is increasing evidence
that the systemic immune system is involved in CNS functioning.
Pro-inflammatory cytokines such as TNF-α can easily cross the
blood brain barrier and complement proteins such as C1q and
C4 are active in brain function (Johnson et al., 1994; Torres et al.,
2001). C1q appears to be especially important in eliminating
unwanted synapses (Stevens et al., 2007). Perhaps the most
important research from an immune-brain perspective is the
involvement of HLA class I proteins in brain development. The
expression of HLA class I proteins occurs throughout the brain
on neurons and even synaptic membranes (Elmer et al., 2013).
It is yet unknown if there are differences in class I alleles in
brain development and this is an area clearly deserving of further
research.
HLA CLASS II ASD ASSOCIATIONS
A maternal-fetal immune interaction has been suggested by Lee
et al. (2006) in which boys with autism and their mothers were
shown to have an increased DR4 frequency over the control
subjects (odds ratios 4.20 and 5.54, respectively). Johnson et al.
(2009) later reported significant transmission disequilibrium for
HLA-DR4 (odds ratio 4.67) from maternal grandparents to
mothers of children with autism, more evidence that HLA-DR4
has amaternal-fetal interaction. Finally, it has been shown inHan
Chinese that the HLA-DRB1 allelic frequencies including DR4
are different in autism subjects vs. control subjects (Chien et al.,
2011). It should be noted that it is common for racial groups to
have different HLA alleles associated with autoimmune diseases.
Warren et al. (1996) also noted that the third hypervariable
region (HVR-3) of certain class II DR4 alleles, referred to as
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TABLE 1 | Demonstrates the SNP complexity in HLA alleles.
COMPLEXITY OF HLA-A ALLELE SEQUENCES
Codon position and DNA sequence
62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83
A*01 CAG GAG ACA CGG AAT ATG AAG GCC CAC TCA CAG ACT GAC CGA GCG AAC CTG GGG ACC CTG CGC GGC
A*02 GG- - - - - - - - - - - -A G- - - - - - - - - - - - - - - - - - - - C- - - - - -T- G- - - - - - - - - - - - - - - - - - - -
A*03 - - - - - - - - - - - - - - - G- - - - - - - - - -G - - - - - - - - - - - - - - - -T- G- - - - - - - - - - - - - - - - - - - -
A*11 - - - - - - - - - - - - - - - G- - - - - - - - - -G - - - - - - - - - - - - - - - -T- G- - - - - - - - - - - - - - - - - - - -
A*23 G- - - - - - - - G- - - -A G- - - - - - - - - - - - - - - - - - - - - - - - - - -A- - - - - - - C- - -T- GC- -T- C- -
A*24 G- - - - - - - - G- - - -A G- - - - - - - - - - - - - - - - - - - - - - - - - - -A- - - - - - - C- - -T- GC- -T- C- -
A*25 -G- A-C - - - - - - - - - G- - - - - - - - - - - - - - - - - - - - - - - - - - -A- -G- - - - C- - -T- GC- -T- C- -
A*26 -G- A-C - - - - - - - - - G- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
A*29 -T- C- - - - - - - - - - - G- - - - - - - - - -G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
A*30 - - - - - - - - - - - - - - - G- - - - - - - - - -G - - - - - - - - - - - - - - - -T- G- - - - - - - - - - - - - - - - - - - -
A*31 - - - - - - - - - - - - - - - G- - - - - - - - - - - - - - - - - -T- - - - - - - -T- G- - - - - - - - - - - - - - - - - - - -
A*32 - - - - - - - - - - - - - - - G- - - - - - - - - - - - - - - - - - - - - - - - - - -A- -G- - - - C- - -T- GC- -T- C- -
A*33 -G- A-C - - - - - - - - - G- - - - - - - - - - - - - - - - - -T- - - - - - - -T- G- - - - - - - - - - - - - - - - - - - -
A*34 -G- A-C - - - - - - - -A G- - - - - - - - - -G - - - - - - - - - - - - - - - -T- G- - - - - - - - - - - - - - - - - - - -
A*36 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
A*43 -T- C- - - - - - - - - - - G- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
A*66 -G- A-C - - - - - - - - - G- - - - - - - - - -G - - - - - - - - - - - - - - - -T- G- - - - - - - - - - - - - - - - - - - -
A*68 -G- A-C - - - - - - - - - G- - - - - - - - - -G - - - - - - - - - - - - - - - -T- G- - - - - - - - - - - - - - - - - - - -
A*69 -G- A-C - - - - - - - - - G- - - - - - - - - -G - - - - - - - - - - - - - - - -T- G- - - - - - - - - - - - - - - - - - - -
A*74 - - - - - - - - - - - - - - - G- - - - - - - - - - - - - - - - - - - - - - - - - - -T- G- - - - - - - - - - - - - - - - - - - -
A*80 G- - - - - - - - - - - - - - G- - - - - - - - - - - - - - - - - - - - A- - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - = same as reference sequence (A*01) = different from reference sequence (A*01)
Approximately one out of three DNA bases in this sequence can be a polymorphism.
FIGURE 3 | Demonstrates the overlapping regions for KIR ligand
binding and antigen-presenting portions of the HLA protein.
the shared epitope (SE), were strongly associated with ASD
(p < 0.01; relative risk = 19.8). In this review, odds ratio
and relative risk, two similar mathematical models to examine
disease risk, are considered equivalent. The HLA-DRB1 SE is a 5
amino acid motif shared by 5 DRB1 alleles. The SE also strongly
associates with the majority of severe rheumatoid arthritis (RA)
patients. The basis for the SE association with ASD and RA is
unknown; however, it has been proposed that the SE peptide
acts as a signal transduction ligand that activates nitric oxide
(NO) and reactive oxygen species production (de Almeida et al.,
2011). It is important to mention that De Almeida et al. (2010)
concluded, in an earlier publication, that the HLA DRB1 shared
epitope peptide is a potent immune-stimulatory ligand that
polarizes naive helper T-cell toward the potent inflammatory
TH17 lineage resulting in higher IL-17 levels detected in autism
subjects (Al-Ayadhi and Mostafa, 2012; Onore et al., 2012).
It should be noted that mothers with SE alleles on either
chromosome were more likely to give birth to an ASD child,
referred to by Warren et al. (1996) as a “maternal attack
against fetal tissue.” The SE observation is important as it
suggested that small peptide epitopes contributed to the high
relative risk in ASD years before the TH17 cell observation was
made.
AUTOANTIBODIES IN AUTISM
One of the most interesting areas of current ASD research is
the observation in at least 8 studies that up to about 10% of
mothers with ASD children and only 0–2% of controls have
humoral antibodies against fetal brain proteins (Croen et al.,
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FIGURE 4 | HLA gene complex encode ligands that react with receptors on the Leukocyte Receptor Complex (LCR) and Natural Killer Cell Gene
Complex (NKC) to influence killing. Blue lines indicate areas of completed research. HLA-A, B, C ligands bind to various KIR receptors encoded on chromosome
19. The DRB1*0401 shared epitope (SE*) is strongly associated with ASD (RR = 19.8) and helps increase TH17 cells. The dashed lines suggest future ASD research
to get a more complete picture on NK-cell killing and antibody production. HLA-DR alleles bind to CD4+ helper T-cells to influence B-cells. HLA-E and MHC Class I
like- sequence A (MICA) proteins are ligands for activating molecules NKG2(3) and NKG2D, respectively, that influence NK-cell killing (chromosome 12).
2008; Braunschweig and Van deWater, 2012). Because HLA class
II molecules are important in antibody production it would be
interesting to know if there is an association between mothers
who make these antibodies and certain DRB1 alleles. The entire
area of maternal antibodies against fetal proteins, the production
of autoantibodies, as well as antibodies to microbial pathogens
should be studied more in ASD (Grether et al., 2016).
CLASS III ASD ASSOCIATIONS
Four of the 25 proteins in the complement system that help or
“complement” antibodies and phagocytic cells to clear pathogens
from the organism are encoded within the HLA complex (C4A,
C4B, C2, and Bf). The C4 complement proteins (C4A and C4B)
are encoded by two separate genes in the HLA class III region
(Torres et al., 2001). It was reported 25 years ago that subjects
with autism had a significant increase in the deletion of the
HLA class III C4B gene (C4B null allele) compared to control
subjects (Warren et al., 1991; Odell et al., 2005). ASD subjects
were also noted to have a significant deficiency in the plasma
C4B protein as determined by an Elisa assay (Warren et al.,
1994). Mostafa and Shehab (2010) have also reported a significant
increase in the deletion of the C4B gene in the Egyptian ASD
population. However, the gene copy number data from qPCR
assays do not entirely agree with the results from the C4B protein
assay, a not uncommon occurrence when comparing genomic
and protein expression data (Kendrick, 2014), thus the solidity
of these results are still uncertain. While the data of Warren
et al. (1996) suggest that the C4B null allele is another common
variant, as it is part of the 44.1 extended haplotype that also
contains the SE, further clarification of the association of C4B
null alleles is required, preferably using samples with known
C4A/C4B DNA complotypes.
There are four proinflammatory cytokines: tumor necrosis
factor-alpha (TNFα), lymphotoxin alpha and beta (LTA and
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LTB), and leukocyte specific transcript-1 (LST1) in the class
III region that are important in inflammation and infection.
TNFα is a proinflammatory, multifunctional cytokine that is
synthesized in numerous cells including NK-cells, macrophages,
granulocytes and T-cells. In the CNS, TNFα is made in NK-cells,
microglia (brain macrophages), astrocytes, and neurons and is
necessary for neural cell differentiation and neuron maturation
and may be critical for proper synaptic pruning (Cacci et al.,
2005). Elevated levels of TNFα are present in ASD patients, as
well as in numerous neurological disorders including multiple
sclerosis, Alzheimer’s Disease, Parkinson’s Disease, ischemia, and
traumatic brain injury (Montgomery and Bowers, 2012). The
three adjacent proinflammatory cytokine genes: lymphotoxin
alpha and beta (LTA and LTB) and leukocyte specific transcript-
1 (LST1) have not been studied as extensively as TNFα
(Ovsyannikova et al., 2010) and deserve further investigation.
There is a developing consensus that there are elevated
plasma levels of proinflammatory cytokines such as IL-1β,
IL-6, IL-8, as well as CCL2 and CCL5 chemokines in ASD
(Grigorenko et al., 2008; Ashwood et al., 2011). Decreased
levels of anti-inflammatory cytokines, most notably TGF-β and
IL-10, have also been reported in ASD (Okada et al., 2007;
Abdallah et al., 2013; Jyonouchi et al., 2014). In addition to
these proinflammatory cytokines, it is interesting to note that
an increase in interferon-gamma (INFγ) and TNFα has been
observed in brain tissue and cerebral spinal fluid of in ASD
subjects (Li et al., 2009). These two cytokines are of special
interest, as TNFα is in the HLA class III region and activates NK-
cells to make large amounts of INFγ (Schoenborn and Wilson,
2007). TNFα also may be important in ASD as it appears to be
a key mediator in neuroinflammation and blood-brain barrier
deterioration (McCoy and Tansey, 2008). TNFα concentrations
are also elevated in several brain disorders including multiple
sclerosis, Alzheimer’s Disease, Parkinson’s Disease, ischemia, and
traumatic brain injury (Montgomery and Bowers, 2012). It is
unclear if TNFα contributes to the disease state or if the higher
concentrations limit brain damage. Finally, another avenue for
investigation, is the class III gene encoding the heat shock protein
70 (HSP70) which is induced in many CNS disorders such as
stroke, epilepsy, trauma and ASD (El-Ansary and Al-Ayadhi,
2012).
INFγ may contribute to ASD pathology by increasing the
enzyme nitric oxide synthase in astrocytes and microglia, and
thereby increasing brain levels of NO. It is thought that activated
immune cells secrete high levels of the free radical NO to
damage pathogens. In the brain however, NO is typically
produced by neurons and it acts as an intercellular messenger
modulating synaptogenesis, dendrite, and axonal growth and
neuronal release of various neurotransmitters (Hess et al., 1993;
Lizasoain et al., 1996). Problems with synaptic development and
plasticity are implicated in the neuropathology of ASD (Ebert and
Greenberg, 2013).
It was reported a couple of years ago that serum levels of IL-17
were elevated in ASD subjects over control subjects suggesting
that T helper 17 (TH17) cells are involved in the etiology of
ASD (Al-Ayadhi and Mostafa, 2012; Onore et al., 2012). TH17
cells are CD4+ helper T-cells characterized by a unique cytokine
profile, mainly high levels of IL-17 thought to be critical for the
development of autoimmunity (Bedoya et al., 2013).
THE IMPORTANCE OF HLA IMMUNITY IN
AUTISM
The HLA gene complex has been considered by many to
be the most important region for immune function in the
human genome. However, the system is not perfect and certain
HLA allotypes and haplotypes have been shown to be strongly
associated with a wide spectrum of autoimmune diseases, such
as Type I diabetes, celiac disease, psoriasis, rheumatoid arthritis
(RA), lupus erthymatosis, myasthenia gravid, Sjogren Syndrome,
and now ASD. The HVR-3 (or shared epitope) that is increased
in ASD (Warren et al., 1996) is also associated with several
autoimmune diseases such as RA, psoriatic arthritis, and systemic
lupus erythematosus (de Almeida et al., 2011). Various HLA
disease associations often have the relative risk factors 15
to 20-fold higher in subjects with autoimmune diseases than
control subjects (Feitsma et al., 2008). The HVR-3 (DRB1∗0401)
association with ASD had a comparable relative risk of 19.8
and 31.5% increase in the ASD population relative to control
subjects, fitting the criteria for a “common variant–common
disease” association.
HLA/KIR COMMON GENETIC VARIANTS
There is currently an intense interest in identifying genetic
variants that increase the risk of developing ASD. The goal of this
paper is to summarize data which suggests that certain HLA/KIR
immune alleles/genes fit the criteria as common genetic variants.
For example, the HLA-A2 allele in independent studies from
three different groups has a >10% increased frequency in the
ASD population than controls (Table 2A). Interestingly, it was
over three decades ago that Stubbs and Magenis (1980) first
implicated HLA-A2 in ASD. A 14 base pair insertion in the
class I non-classical HLA-G loci is strongly associated with ASD
(Guerini et al., 2015) and is clearly a common variant at 18% over
controls (Table 2A).
The DR4 allele has higher frequencies of 18.94 and 7.64%
in two ASD populations over control populations suggesting
that DR4 is a common variant (Table 2A). Warren et al. (1996)
presented data that strongly suggested that the shared epitope
is a common genetic variant with a 31.5% increase of ASD over
control subjects (Table 2A).
Examination of KIR gene frequencies suggests that certain
activating genes are common variants with ASD frequency
differentials well above 5% in two different publications (Torres
et al., 2012b; Guerini et al., 2014). The KIR region in the leukocyte
receptor complex (LRC) is not typical as KIR haplotypes are
based on different combination of activating and inhibiting genes
that influence NK-cell killing (Pyo et al., 2013; Torres et al.,
2016). Gene frequency analyses suggest that three activating
genes (3DS1, 2DS1, and 2DS2) are common variants (Table 2B).
Additionally, examinations of all activating KIR genes (aKIR)
indicate an increase in total activating genes in ASD over
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TABLE 2 | (A) Suggests that HLA class I and class II alleles are common genetic variants (>5%). (B) Suggests that KIR genes and KIR gene-content
haplotypes are common genetic variants.
Variables p-value Odds ratio Subjects (%) Controls (%) Common variant (>5%)
(A) HLA
Class I alleles
A21 0.0002 2.22 101/258 (39.1%) 75/265 (28.3%) 10.8
A22 0.001 3.02 30/70 (42.8%) 54/200 (27.0%) 15.8
G 14 bp(+/+)3 0.01 2.70 19/74 (25.7%) 3/39 (7.7%) 18.0
Class II alleles
DR44 0.003 3.24 10/32 (31.3%) 117/950 (12.3%) 19.0
DR45 0.004 1.60 50/205 (24.4%) 68089/406503(16.8%) 7.6
SE6 <0.001 19.80 17/50 (34.0%) 2/79 (2.5%) 31.5
Class III alleles
C4BQ06 0.03 4.60 27/50 (54.0%) 16/79 (20.2%) 13.8
(B) KIR
Kir genes
3DS17 0.004 1.89 83/158 (52.5%) 65/176 (36.9%) 15.6
2DS17 0.00007 2.45 95/158 (60.1%) 67/176 (38.1%) 22.0
2DS28 0.030 1.83 63/90 (70.0%) 140/250 (56.0%) 14.0
aKIR*7 0.0004 1.36 126/158 (79.7%) 128/176 (72.7%) 7.0
Kir haplotypes
cA019 0.00001 0.53 110/178 (61.8%) 6248/9024 (69.2%) −7.4 (protective)
cB019 0.005 1.69 41/178 (23.0%) 1184/9024 (13.1%) 9.9
cB01/tA019 0.002 2.06 25/170 (14.7%) 697/9024 (7.7%) 7.0
Kir genes + HLA ligands
aKIR + HLA7 0.0006 1.56 117/155 (75.5%) 104/164 (63.4%) 12.1
1Torres et al., 2006.
2Al-Hakbany et al., 2014.
3Guerini et al., 2015.
4Lee et al., 2006.
5Torres et al., 2002.
6Warren et al., 1996.
7Torres et al., 2012b.
8Guerini et al., 2014.
9Torres et al., 2016.
control subjects. KIR gene-content haplotypes have centromeric
and telomeric parts that join at the junction between 3DP1
and 2DL4 (Figure 5). Examination of the KIR haplotypes
suggests that three partial KIR haplotypes (tA01/cA01/cB01)
and a complete KIR gene-content haplotype (cB01/tA01)
all meet common variant criteria (Table 2B; Torres et al.,
2016).
AUTISM IMMUNOGENETICS
Immunogenetics commonly refers to the strong association of
HLA alleles/genes with autoimmune diseases (Shiina et al., 2004).
We wish to propose that much of the immune dysfunction in
ASD has a basis in the HLA /KIR gene complexes; thus, we have
coined the term Autism Immunogenetics. Although, many of the
multiple thousands of HLA alleles are rare there are hundreds
of weIl-characterized HLA class I and class II alleles that make
up a significant part of the genetic diversity of the 900 gene
Immunome.
One must remember that the entire 200 genes in the HLA
gene complex are inherited as large 4.5 million base pair extended
haplotypes and a couple of these large extended haplotypes have
been associated with autism (Warren et al., 1996). The association
of the A2, DR4 alleles and C4B null allele with ASD may be
due to the fact that they are part of the extended haplotype
44.1 that is ASD associated (Figure 4; Table 2). However, the
important observation is that all are common genetic variants.
It would be interesting to know which extended haplotypes have
theHLA-G 14 bp insertion as it strongly associates with ASD. The
shared epitope peptide may be the most important as it directs
helper T-cells to the TH17 lineage which appears to be important
in the pathogenesis of autoimmune neuroinflammatory diseases
including ASD (Figure 4; Onore et al., 2012; Choi et al.,
2016). A recent publication suggested that maternal TH17 cells
could induce an ASD-like phenotype in newborn mice and
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FIGURE 5 | Genes present in KIR gene-content haplotypes. Only genes present in a haplotype are listed under the gene column: for example, 2DS2 is absent in
the first two haplotypes, but present in the last four haplotypes. Certain haplotype can have 2DL2 or 2DL3 and other haplotype can have 2DL1 or 2DS1 and 2DS1 or
2DS4. The complete gene-content KIR haplotype (cB01/tA01) is a proposed common variant.
that blocking antibodies to IL-17a ameliorated these symptoms
(Choi et al., 2016). The high relative risk for the SE in ASD
noted by Warren et al. (1996) may be due to an increase in
TH17cells.
CONCLUDING REMARKS
A significant body of evidence has accumulated over the past
30 plus years to demonstrate that specific variants in immune
system genes, involving both innate and adaptive immunity
pathways, are associated with the incidence of ASD. However,
such associations have not been detected by genome wide
screening methods, e.g., GWAS, and therefore have been widely
ignored by the majority of investigators in the autism research
field. The inability to detect immune gene ASD associations
by GWAS techniques is fully understandable, considering the
massive genetic complexity of the “Immunome,” with more
than one hundred thousand polymorphisms localized within
a small segment (<5%) of the total genome. Thus, highly
focused methods, usually PCR or sequence-based typing, are
required to reveal disease associations with immune genes or
haplotypes, and these can usually be detected using relatively
small number of patient and control samples. Next-Generation
Sequencing methods to rapidly sequence the HLA locus
are well developed for such autism immunogenetic studies
(Nelson et al., 2015; Carapito et al., in press). Indeed, as
summarized in Table 2, several HLA and KIR gene variants
that meet the “common variant–common disease” criteria
have been identified using relatively small sample sizes: in
the low hundreds. Perhaps the most interesting observation
concerning common genetic variants is the 12% increase of
the HLA ligand /KIR activating gene complex in autism over
the control populations (Table 2). We argue strongly that
additional efforts be focused on identifying and characterizing
the role of immune genes in the etiology of ASD, particularly
using phenotypically well-defined populations of autistic
subjects.
The data summarized in this review raises numerous
questions in addition to those raised earlier in this paper. For
example, how do different immune gene variants influence
brain development and function? While it is clear that many
HLA proteins are expressed in or on neural cells and they
can modulate the activity of downstream effector cells or
proteins, such as NK-cells or pro-inflammatory cytokines,
details on how they actually function are unknown. The fact
that a single amino acid change in certain HLA class I and
II proteins can alter their functionality makes such studies
extremely challenging. For example, single DNA base differences
in HLA-C alleles encode different amino acids which are
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DNA Ligand Receptor
Codon AAC HLA-C amino acid #80 ASN—————- KIR-2DS2 and 2DL2
Codon AAA HLA-C amino acid #80 LYS —————- KIR-2DS1 and 2DL1
ligands for different KIR receptors (below) (Torres et al.,
2016).
An additional question that needs to be addressed is why
do up to 10% of mothers with ASD children have humoral
antibodies against fetal brain proteins (compared to 0–2% of
control mothers) and do these autoantibodies adversely affect
fetal brain development? Furthermore, does the 14 bp insertion
in the HLA G gene that occurs more frequently in ASD
subjects and their mothers impair immune tolerance during
pregnancy and increase the risk of in utero developmental
problems?
HLA ALLELES AND KIR GENES AS
COMMON GENETIC VARIANTS IN ASD
The observations that several HLA alleles as well as several
KIR genes and haplotypes appear to be common genetic
variants associated with ASD (Table 2) raises the question
as to whether or not other immune genes (for example
HLA-E, HLA-F, and MICA) have similar ASD associations.
These issues should be addressed in future studies. In
summary, by further understanding how immune gene variants
participate in the etiology of ASD, it may be possible to:
#1 develop biological markers to predict ASD at an earlier
stage or even in utero and #2 develop targeted pharmaceutical
molecules such as monoclonal antibodies, decoy peptides, and
special nucleic acid molecules against SE, HLA, and KIR
molecules.
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